- Describe the mechanism of action, efficacy, and pleiotropic properties of GLP‐1 receptor agonists (GLP‐1 RA)
- Recognize the growing role of GLP‐1 RAs in type 2 diabetes management algorithms
- Distinguish among the available GLP‐1 RAs based on mode of administration, duration of action, and renal dosing
- Apply data on cardiovascular risk reduction demonstrated by individual GLP‐1 RAs into practice
Session supported by Novo Nordisk, Inc.